|
Guest Book is Back!
|
PRA Disease The genetic disorder, prcd-PRA , causes cells in the retina at the back of the eye to degenerate and die, even though the cells seem to develop normally early in life. The “rod” cells operate in low light levels and are the first to lose normal function. Night blindness results. Then the “cone” cells gradually lose their normal function in full light situations. Most affected dogs will eventually be blind. Typically, the clinical disease is recognized first in early adolescence or early adulthood. Since age at onset of disease varies among breeds, you should read specific information for your dog. Diagnosis of retinal disease can be difficult. Conditions that seem to be prcd-PRA might instead be another disease and might not be inherited. OptiGen’s genetic test assists in making the diagnosis. It’s important to remember that not all retinal disease is PRA and not all PRA is the prcd form of PRA. Annual eye exams by a veterinary ophthalmologist will build a history of eye health that will help to diagnose disease. Unfortunately, at this time there is no treatment or cure for PRA. If your dog is affected, you may find it helpful to read about other owners’ experiences living with blind dogs. (suggested links:www.eyevet.org and www.blinddogs.com) Inheritance
| |||||||||||||||||||||
| Possible results using the OptiGen prcd test | |||
| Genotype | Risk Group | Significance For Breeding | Risk of prcd Disease |
| Homozygous Normal | Normal/Clear | Can be bred to
any dog, extremely low risk of producing affecteds |
Extremely low |
| Heterozygous | Carrier | Should be bred
only to Normal/ Clear to remove risk of producing affecteds |
Extremely low |
| Homozygous Mutant | Affected | Should be bred
only to Normal/ Clear to remove risk of producing affecteds |
Very high |
The research leading to this discovery was undertaken by scientists at the James A. Baker Institute of Animal Health at Cornell University's College of Veterinary Medicine in Ithaca, New York. Initial data are published in volume 95 of the March, 1998 issue of the Proc. National Academy of Sciences. Publication of the prcd mutation is being prepared. The patented technology underlying this test is under exclusive license to OptiGen from Cornell Research Foundation, Inc.